Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $184.72 +1.74%
EPS Growth %: -12.5%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -12.5%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
- AM Best Assigns Credit Ratings to Kuwait Islamic Takaful Insurance Company K.S.C. (closed)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
